Dyne Therapeutics’ (DYN) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report released on Wednesday,Benzinga reports. HC Wainwright currently has a $55.00 price target on the stock.

Several other equities analysts also recently weighed in on DYN. Guggenheim lifted their price target on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 15th. Stifel Nicolaus upped their target price on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Piper Sandler reissued an “overweight” rating and set a $53.00 price target on shares of Dyne Therapeutics in a report on Monday, September 23rd. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $43.00 to $35.00 in a research report on Thursday, October 24th. Finally, StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.40.

Dyne Therapeutics Trading Down 6.3 %

DYN opened at $28.39 on Wednesday. The firm’s 50 day simple moving average is $32.48 and its two-hundred day simple moving average is $35.10. The company has a market capitalization of $2.89 billion, a PE ratio of -7.97 and a beta of 1.10. Dyne Therapeutics has a 1-year low of $9.76 and a 1-year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Equities analysts forecast that Dyne Therapeutics will post -3.02 earnings per share for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In related news, Director Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $36.45, for a total value of $2,894,530.95. Following the completion of the transaction, the director now owns 234,127 shares in the company, valued at approximately $8,533,929.15. This trade represents a 25.33 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Richard William Scalzo sold 1,390 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the sale, the senior vice president now owns 98,568 shares in the company, valued at approximately $3,405,524.40. This trade represents a 1.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 158,975 shares of company stock valued at $5,693,789 in the last ninety days. Corporate insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC lifted its position in Dyne Therapeutics by 69.7% in the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after buying an additional 3,707,734 shares during the last quarter. RTW Investments LP raised its stake in shares of Dyne Therapeutics by 6.8% in the third quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock valued at $244,926,000 after acquiring an additional 431,503 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Dyne Therapeutics by 47.3% in the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock worth $244,755,000 after acquiring an additional 2,189,339 shares during the last quarter. RA Capital Management L.P. boosted its stake in shares of Dyne Therapeutics by 5.5% during the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock worth $229,211,000 after purchasing an additional 331,940 shares during the period. Finally, State Street Corp grew its holdings in Dyne Therapeutics by 13.8% during the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after purchasing an additional 440,890 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.